福莫特罗与茚达特罗治疗慢性阻塞性肺疾病的系统评价  

Systematic Evaluation of Formoterol and Indatero in the Treatment of Chronic Obstructive Pulmonary Disease

作　　者：刘秀书[1] 曹艳[1] 杜岚[1] 邹爱英[1] 尹世强[2] 

机构地区：[1]天津中医药大学第二附属医院药学部,天津300150 [2]国药控股天津有限公司,天津300040

出　　处：《中国医院用药评价与分析》2015年第6期765-769,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金："十二五"国家科技支撑计划课题"安全合理用药评价和干预技术研究与应用"(No.2013BAI06B04)

摘　　要：目的:评价福莫特罗与茚达特罗治疗慢性阻塞性肺疾病(COPD)的疗效和安全性。方法:检索中英文数据库,福莫特罗对比安慰剂或茚达特罗治疗COPD的随机对照试验(RCT)和系统评价(SR),对纳入的RCT进行方法学质量评价和meta分析。结果:与安慰剂比较,福莫特罗可显著改善COPD患者生活质量,差异具有统计学意义(P<0.01);与福莫特罗比较,茚达特罗可显著改善COPD患者用力1秒呼气量,差异具有统计学意义(P<0.01);福莫特罗与安慰剂或茚达特罗其余指标比较差异均无统计学意义(P>0.05)。结论:福莫特罗和茚达特罗均可改善COPD患者生活质量,且茚达特罗还可显著改善患者肺功能,因此,茚达特罗是值得在临床推广的COPD治疗方法。OBJECTIVE：To evaluate the efficacy and safety of fomoterol and indatero in the treatment of chronic obstructive pulmonary disease （ COPD） .METHODS： The databases either in English or Chinese were searched for randomized controlled trials （ RCTs） or systematic review of formoterol as compared with placebo or indacaterol for treatment of COPD.The included RCTs were subjected to evaluation of the methodological quality and meta-analysis. RESULTS：Compared with placebo, formoterol significantly improved the quality of life of patients with COPD, and the difference was statistically significant （P〈0.01）;compared with formoterol, indinavir significantly improved FEV1 in patients with COPD, and the difference was statistically significant （ P〈0.01 ） .There were no significant differences between formoterol and placebo or indinavir in other indices （ P 〉0.05 ） .CONCLUSIONS： Both formoterol and indacaterol can improve the quality of life of patients with COPD, and indacaterol also can significantly improve lung function in patients with COPD, indatero, therefore, is worthy of wide clinical application in the treatment of COPD.

关 键 词：肺疾病 慢性阻塞性 META分析 随机对照试验 福莫特罗 系统评价 

分 类 号：R974.3[医药卫生—药品] R563.9[医药卫生—药学]